Vifor Pharma Group 보도자료

• Update on the timeline for Vifor Pharma tender offer 2022-05-13 10:00
• Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients 2022-04-28 15:30
• 94th Vifor Pharma Group Annual General Meeting 2022-04-27 17:25
• DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy 2022-04-04 14:10
• Publication of definitive end result for Vifor Pharma tender offer 2022-03-28 15:00
• Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent 2022-03-23 16:40
• Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful 2022-03-08 17:05
• Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent 2022-03-03 17:30
• Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients 2022-02-28 15:40
• Vifor Pharma appoints two new members to the Executive Committee 2022-02-03 09:35
• VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitis 2022-01-20 10:00
• Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa® 2021-12-21 17:30
• Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation 2021-12-20 15:40
• Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma 2021-12-16 15:30
• CSL Limited announces tender offer to acquire Vifor Pharma Ltd 2021-12-14 17:05